Use of butane, propane, nitrous oxide and other inhalants can create a risk of freezing burns from contact with the extremely cold liquid (See aerosol burn). The risk of such contact is greatly increased by the impaired judgement and motor coordination brought on by inhalant intoxication. Benzene use can cause bone marrow depression. It is also a known carcinogen. Toluene can damage myelin.Toxicity may also result from the pharmacological properties of the drug; excess NMDA antagonism can completely block calcium influx into neurons and provoke cell death through apoptosis, although this is more likely to be a long-term result of chronic solvent use than a consequence of short-term use. Sudden sniffing death syndrome
Sudden sniffing death syndrome is commonly known as SSDS. Inhaling butane gas can cause drowsiness, unconsciousness, asphyxia, and cardiac arrhythmia. Butane is the most commonly misused volatile solvent in the UK and caused 52% of solvent-related deaths in 2000. When butane is sprayed directly into the throat, the jet of fluid can cool rapidly to −20 °C by adiabatic expansion, causing prolonged laryngospasm.Some inhalants can also indirectly cause sudden death by cardiac arrest, in a syndrome known as "sudden sniffing death".
Phendimetrazine (Bontril, Adipost, Anorex-SR, Appecon, Melfiat, Obezine, Phendiet, Plegine, Prelu-2, Statobex) is a stimulant drug of the morpholine chemical class used as an appetite suppressant. Pharmacology
Phendimetrazine functions as a prodrug to phenmetrazine; approximately 30 percent of an oral dose is converted into it. Phendimetrazine can essentially be thought of as an extended-release formulation of phenmetrazine with less potential for abuse. Phendimetrazine is an anorectic drug which acts as a norepinephrine-dopamine releasing agent (NDRA).As an amphetamine congener, its structure incorporates the backbone of methamphetamine, a potent CNS stimulant. While the addition of an N-methyl group to  amphetamine significantly increases its potency and bioavailability, methylation of phenmetrazine renders the compound virtually inactive. However, phendimetrazine is a prodrug for phenmetrazine which acts as the active metabolite. Phendimetrazine possesses preferable pharmacokinetics over phenmetrazine as a therapeutic agent because its metabolization by demethylases produces a more steady and prolonged exposure of active drug within the body. This decreases abuse potential as the peak blood-concentration of active phenmetrazine thats produced from a single dose of phendimetrazine is lower than a single therapeutically equivalent dose of phenmetrazine. Indicated as a short-term secondary treatment for exogenous obesity, phendimetrazine immediate-release 35mg tablets are typically consumed one hour before meals, not to exceed three doses daily. Phendimetrazine is also manufactured as a 105mg extended-release capsule for once daily dosing, typically consumed 30 to 60 minutes before a morning meal. Whereas the immediate-release formulation has a maximum daily dosage of 210mg (6 tablets), the extended-release capsules have a maximum daily dosage of 105mg (one capsule).